TY - JOUR AU - Garassino, Marina C. AU - Broggini, Massimo PY - 2015 TI - Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?—An update incorporating the DELTA trial data JF - Journal of Thoracic Disease; Vol 7, No 3 (March 30, 2015): Journal of Thoracic Disease Y2 - 2015 KW - N2 - At present, for the treatment of second line advanced nonsmall cell lung cancer (NSCLC), three drugs are now available, pemetrexed, docetaxel and erlotinib (1-3). Docetaxel was registered in a superiority trial over placebo and it became the first second line approved at the beginning of this century, while erlotinib was licensed with a pivotal trial against placebo five years later (2). UR - https://jtd.amegroups.org/article/view/4073